Background: Follicular lymphoma (FL) patients may receive many lines of treatment (LoTs)
to maintain disease control. Current clinical outcomes in later LoTs (≥ 3 rd) are not well …

The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular
lymphoma (FL) patients on 3 rd line of treatment (LoT) or higher, for whom existing data are …

Background: Follicular lymphoma (FL) is an indolent, yet incurable disease, and patients
often require several lines of therapy throughout their lifetime (Batlevi et al. Blood Cancer J …

e19548 Background: Patients with follicular lymphoma (FL) can have high response rates to
early lines of treatment. However, among FL patients relapsed/refractory (r/r) after≥ 2 prior …

Background: Novel therapies for multiply relapsed follicular lymphoma (FL) are often
evaluated in single arm trials with no comparative data on patients receiving usual care. This …

Follicular lymphoma (FL) is a clinically heterogeneous disease. The need for treatment,
treatment sequencing, number of treatment lines, and its association with survival have not …

This study (ReCORD-FL) sought to construct a historical control cohort to augment single-
arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 …

Abstract Abstract 154 Background Follicular lymphoma (FL) has an indolent course during
which patients (pts) receive multiple lines of active treatments ranging from single-agent …

Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a
number of highly effective therapies. Patients and methods: We set out to determine …

Background Patients with follicular lymphoma (FL) can have high response rates to early
lines of treatment. However, among FL patients relapsed/refractory (r/r) after≥ 2 prior lines …